Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricAZNAstraZeneca PLCNVSNovartis AGMRKMerck & Co.
Snapshot
Price$168.69$154.07$126.06
Market cap$284.73B$261.56B$319.99B
Valuation
P/E25.9x21.4x34.7x
Forward P/E19.4x19.5x49.6x
Growth
Revenue growth9.9%5.8%2.9%
EPS growth33.7%9.3%-48.3%
Profitability
Net margin17.2%24.1%13.6%
ROE22.3%31.7%17.9%
Balance sheet & cash
Debt / equity0.61x0.77x0.94x
Free cash flow yield3.1%4.2%2.9%
Dividend yield1.7%2.9%3.0%
Verdict
Investment ratingFavorable· 62Favorable· 67Weak· 40

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearAZNtoday $169NVStoday $154MRKtoday $126
2027$169.17 – $248.11+47% CAGR$126.26 – $185.19+20% CAGR$96.44 – $141.44+12% CAGR
2028$226.19 – $331.75+40% CAGR$137.97 – $202.35+15% CAGR$98.36 – $144.27+7% CAGR
2029$302.44 – $443.58+38% CAGR$150.76 – $221.11+13% CAGR$100.33 – $147.15+5% CAGR
2030$404.40 – $593.11+37% CAGR$164.73 – $241.61+12% CAGR$102.34 – $150.10+4% CAGR
2031$540.72 – $793.05+36% CAGR$180.00 – $264.01+11% CAGR$104.39 – $153.10+4% CAGR
5-yr CAGR26.2% – 36.3%3.2% – 11.4%-3.7% – 4.0%